Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Date publication

octobre 2016

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LHERMITTE Benoît

Tous les auteurs :
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27143690

Résumé

EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter.

Mots clés

Adult, Aged, Brain Neoplasms, drug therapy, Chemoradiotherapy, methods, DNA Methylation, DNA Modification Methylases, genetics, DNA Repair Enzymes, genetics, Dacarbazine, administration & dosage, Female, Glioblastoma, drug therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Promoter Regions, Genetic, genetics, Proportional Hazards Models, Sirolimus, administration & dosage, Tumor Suppressor Proteins, genetics, Young Adult

Référence

Clin. Cancer Res.. 2016 Oct 1;22(19):4797-4806